Abstract 4696
Background
Symptom burden and reduced quality of life are considerable hurdles in cancer treatment. The Patient-Reported Outcomes Measurement Information System (PROMIS) assesses physical and psychosocial functional status in clinical and research settings. We use PROMIS scores to establish mean symptom burden within a breast cancer patient population, identifying how subgroups compare to one another, examining potential drivers, and characterizing severe symptom burden between subgroups.
Methods
New cancer patients at the UCSF Breast Care Center (BCC) receive electronic intake questionnaires assessing demographics, health history, and 8 PROMIS domains: depression, anxiety, fatigue, sleep-related impairment and disturbance, cognitive function, applied cognition and physical function. Patients were separated by age and stage of cancer and mean PROMIS reference values for each group were calculated using the NCI’s Health Measures scoring system. We computed enrichment of higher levels of anxiety, sleep impairment, fatigue, physical function impairment, and cognitive decline in metastatic patients versus all other cases.
Results
Compared to stage 0-III, BCC stage IV patients had lower mean values for all assessed domains (p < 0.05). Within the stage IV population, high levels of anxiety were uniquely predictive of low functional status in 6 out of the other 7 domains. The stage IV population was significantly enriched for severe symptomatology in all domains except sleep-related impairment and disturbance when compared to the stage 0-III population.
Conclusions
PROMIS scores indicate that stage IV patients have impaired quality of life in multiple domains. Reference values for demographic groups provide improved guidance in tailoring supportive care referrals. Anxiety emerged as one of the biggest drivers of impairment of other physical, mental, and social functions and thus increased priority addressing anxiety early will likely correspond with improved symptom burden. Our analysis on quality of life will also help determine appropriate thresholds of intervention to trigger referrals and manage a patient’s quality-of-life trajectory more systematically.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Athena Breast Health Network.
Funding
Athena Breast Health Network, University of California, San Francisco.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3911 - Defining a SUV decrease cut-off in PET/CT response monitoring after one cycle of preoperative breast cancer chemotherapy
Presenter: Marcin Kubeczko
Session: Poster Display session 2
Resources:
Abstract
1849 - Effect of thioredoxin 1 quantity detection to complement the mammography in breast cancer diagnosis
Presenter: Younju Lee
Session: Poster Display session 2
Resources:
Abstract
2221 - Identification of ultralow risk breast cancer patients (probable overdiagnosis)
Presenter: Salvador Gamez Casado
Session: Poster Display session 2
Resources:
Abstract
5291 - Prevalence of Vitamin D3 deficiency among women with early breast cancer receiving chemotherapy in an oncology dayward.
Presenter: Warner Finstad
Session: Poster Display session 2
Resources:
Abstract
4247 - Changes in ER pathway activity score during neoadjuvant letrozole to assess therapy response and predict disease free survival (DFS) in ER positive breast cancer patients
Presenter: Arran Turnbull
Session: Poster Display session 2
Resources:
Abstract
568 - Second primary malignancies in patients with breast cancer.
Presenter: Carlos Erasun Lecuona
Session: Poster Display session 2
Resources:
Abstract
1428 - Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab (TP) with either palbociclib + letrozole (Pal+L) or paclitaxel (Pac) for elderly patients with estrogen receptor & HER2 positive (ER+/HER2+) Breast Cancer (BC) (International Breast Cancer Study Group IBCSG 55-17, TOUCH)
Presenter: Laura Biganzoli
Session: Poster Display session 2
Resources:
Abstract
1479 - Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): an open label randomized phase 2 trial
Presenter: Heather McArthur
Session: Poster Display session 2
Resources:
Abstract
1481 - A randomized phase 2 study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy
Presenter: Heather McArthur
Session: Poster Display session 2
Resources:
Abstract
4334 - ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer.
Presenter: Michail Ignatiadis
Session: Poster Display session 2
Resources:
Abstract